# MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention

> **NCT03961334** · PHASE3 · UNKNOWN · sponsor: **University of Zurich** · enrollment: 620 (estimated)

## Conditions studied

- Stroke, Ischemic

## Interventions

- **DRUG:** Dabigatran
- **DRUG:** Apixaban
- **DRUG:** Edoxaban
- **DRUG:** Aspirin
- **DRUG:** Clopidogrel

## Key facts

- **NCT ID:** NCT03961334
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-05
- **Primary completion:** 2025-01-31
- **Final completion:** 2026-01-31
- **Target enrollment:** 620 (ESTIMATED)
- **Last updated:** 2023-08-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03961334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03961334, "MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03961334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*